featured
Overall Survival Did Not Differ Between Axitinib Versus Sorafenib Groups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Axitinib Versus Sorafenib as Second-Line Treatment for Advanced Renal Cell Carcinoma: Overall Survival Analysis and Updated Results From a Randomised Phase 3 Trial
Lancet Oncol 2013 Apr 19;[EPub Ahead of Print], RJ Motzer, B Escudier, P Tomczak, et alFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.